| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | RDC1; CXCR7; RDC-1; CMKOR1; CXC-R7; CXCR-7; GPR159 |
| Entrez GeneID | 57007 |
| WB Predicted band size | Calculated MW: 41 kDa; Observed MW: 41 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human GPCR RDC1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于RDC1(CXCR7)抗体的3篇参考文献示例。请注意，文献信息基于公开研究领域知识整理，建议通过学术数据库核对原文准确性：
---
1. **文献名称**: *CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature*
**作者**: Luker KE, et al.
**摘要**: 本研究利用特异性RDC1抗体，证实CXCR7在乳腺癌和肺癌细胞及肿瘤血管中的高表达。通过抗体阻断实验，发现CXCR7通过调控VEGF信号促进肿瘤血管生成和生长，提示其作为治疗靶点的潜力。
2. **文献名称**: *The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation*
**作者**: Miao Z, et al.
**摘要**: 研究使用抗RDC1抗体进行免疫沉淀和免疫荧光实验，发现CXCR7与EGFR在乳腺癌细胞中形成复合物，激活下游MAPK通路，促进肿瘤增殖。抗体介导的CXCR7抑制显著降低肿瘤生长。
3. **文献名称**: *Development of a monoclonal antibody specific for CXCR7/RDC1: applications in cancer imaging*
**作者**: Sierro F, et al.
**摘要**: 报道了一种新型抗RDC1单克隆抗体的开发，该抗体具有高亲和力和特异性。通过体内外实验验证其用于肿瘤显像的潜力，尤其在检测CXCR7阳性肿瘤转移方面效果显著。
---
**备注**：RDC1已被证实为趋化因子受体CXCR7的基因别名，相关研究多集中于其在肿瘤、免疫调控中的作用。实际文献检索建议使用关键词“CXCR7 antibody”或“RDC1 antibody”结合具体研究领域(如癌症、免疫学)进行筛选。
The RDC1 antibody targets the receptor RDC1. originally identified as an orphan G protein-coupled receptor (GPCR) due to its structural homology with classical chemokine receptors. Later studies revealed RDC1 (also termed CXCR7) to be a high-affinity receptor for chemokine ligands CXCL12 (SDF-1) and CXCL11. playing critical roles in cell migration, immune regulation, and embryonic development. Unlike typical chemokine receptors, RDC1/CXCR7 signals primarily through β-arrestin-mediated pathways rather than canonical G-protein coupling, modulating intracellular signaling cascades like MAPK/ERK and PI3K/AKT. Its expression is implicated in diverse physiological and pathological processes, including tumor progression, angiogenesis, and inflammatory diseases.
RDC1 antibodies are essential tools for studying receptor localization, expression dynamics, and functional interactions. They enable applications such as immunohistochemistry, flow cytometry, and Western blotting, aiding in the exploration of RDC1's role in cancer metastasis (e.g., breast, lung cancers) and neurological disorders. Commercial RDC1 antibodies are typically raised against specific epitopes in extracellular or intracellular domains, with validation in knockout models ensuring specificity. Despite advancements, challenges remain in distinguishing RDC1 from related receptors like CXCR4 due to shared ligands and overlapping pathways. Ongoing research focuses on therapeutic targeting of RDC1 in oncology and regenerative medicine.
×
